Spirulina and giant cell arteritis: IL-6 pathway, high-dose prednisolone, tocilizumab, and visual loss risk

GCA pathophysiology

Granulomatous arterial inflammation: Plasmacytoid dendritic cells in the adventitia activate CD4+ Th1 and Th17 cells via IL-12 and IL-23. Th1 cells produce IFN-γ, activating macrophages that fuse into multinucleated giant cells. Th17 cells produce IL-17A, which drives vasa vasorum neovascularisation and smooth muscle hyperplasia causing luminal narrowing. IL-6 is abundantly produced by activated macrophages and mediates the systemic inflammatory response (fever, weight loss, elevated ESR/CRP).
NOX2 in GCA: Activated macrophages and giant cells express NOX2; oxidative burst contributes to arterial wall damage and smooth muscle destruction. Phycocyanobilin’s NOX2 inhibition and NF-κB suppression are mechanistically relevant to reducing macrophage-mediated arterial damage, but the immunosuppressive treatment context creates a conflicting NK stimulation consideration.
Polymyalgia rheumatica (PMR) overlap: 50% of GCA patients have coexistent PMR (shoulder and hip girdle pain/stiffness). PMR without GCA requires lower-dose prednisolone (15–25 mg/day); GCA requires 40–60 mg/day (visual involvement: 1000 mg IV methylprednisolone for 3 days). The NK stimulation concern applies at both dose levels but is greater at GCA immunosuppressive doses.

GCA is primarily T cell (Th1/Th17) and macrophage-driven, not NK cell-driven. However, patients with GCA are typically on high-dose immunosuppressive corticosteroids (40–60 mg prednisolone), and some are on tocilizumab (IL-6 receptor blockade, a biologic immunosuppressant). The NK stimulation concern in GCA arises from the immunosuppressive treatment rather than the disease mechanism itself. At prednisolone ≥20–40 mg/day or on tocilizumab: discuss with rheumatologist before starting spirulina. Caution is warranted given the depth of immunosuppression.

Visual loss is an emergency: Anterior ischaemic optic neuropathy (AION) from ophthalmic or posterior ciliary artery involvement causes sudden, often painless monocular visual loss. This is an ophthalmological emergency requiring immediate high-dose corticosteroid therapy (IV methylprednisolone 1000 mg/day for 3 days) to preserve vision in the other eye. Spirulina has no role in managing, preventing, or treating GCA visual complications. Any new visual symptoms in a person with GCA or suspected GCA require same-day medical assessment.

Prednisolone at 40–60 mg/day significantly suppresses T, NK, and macrophage function. No pharmacokinetic interaction with spirulina. Pharmacodynamic concern: spirulina NK stimulation may partially oppose the immunosuppressive effect; this is the basis for the NK stimulation caution in GCA. At full remission and prednisone tapered below 10 mg/day (maintenance), the concern becomes lower; discuss with treating rheumatologist.

Tocilizumab (Actemra) is approved for GCA and used alongside or to replace prednisolone as a steroid-sparing agent. It is a biologic immunosuppressant (monoclonal antibody, not CYP-metabolised); no pharmacokinetic interaction with spirulina. Pharmacodynamic concern: NK cells express IL-6 receptors and IL-6 modulates NK cell function; tocilizumab reduces NK cytotoxicity as part of its mechanism. Spirulina NK stimulation in the context of tocilizumab creates an uncertain interaction; avoid until discussed with rheumatologist.

Low-dose methotrexate (7.5–15 mg/week) is used as a steroid-sparing adjunct in GCA. No pharmacokinetic interaction with spirulina. Methotrexate and spirulina both have anti-inflammatory properties via different mechanisms. The NK concern at low-dose MTX is intermediate (lower than at high-dose immunosuppression but higher than no immunosuppression).

Low-dose aspirin (75–100 mg/day) is often co-prescribed in GCA to reduce ischaemic events. Spirulina’s mild antiplatelet effects at ≥5 g/day add to aspirin’s antiplatelet activity. In active GCA at risk of ischaemic complications, this additive antiplatelet effect is clinically acceptable but inform the treating physician.

GCA typically requires 1–2 years of steroid tapering. As prednisolone is tapered below 10 mg/day (physiological range), the NK stimulation concern from immunosuppressive doses diminishes. Spirulina may be more appropriate to start during the maintenance/tapering phase than during the acute immunosuppressive phase — discuss with rheumatologist at each review.

Active GCA on high-dose prednisolone (≥20 mg/day) or tocilizumab: defer spirulina until discussed with rheumatologist; NK stimulation concern at immunosuppressive doses
PMR without GCA on 15–25 mg prednisolone: intermediate concern; discuss with prescribing physician
GCA in remission, prednisolone tapered to ≤7.5 mg/day: NK concern lower; 1–2 g/day starting dose, monitor ESR/CRP at next routine rheumatology appointment
Never delay seeking urgent medical help for new visual symptoms, jaw claudication, or temple pain to try spirulina first